Cervical intraepithelial neoplasia progression and regression among women living with HIV in Zambia
HIV Medicine · 2025
DOI: 10.1111/hiv.70134 ↗Kurz gefasst
Fachartikel in der Zeitschrift HIV Medicine, 2025. Verfasst von John Andoh und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland. Hauptthemen laut MEDLINE: HIV Infections, Uterine Cervical Dysplasia, Papillomavirus Infections, Uterine Cervical Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung, World Health Organization.
Abstract (Originalsprache)
Objectives
Cervical screening and precancer treatment are less effective in women living with HIV (WLWH) than in women without HIV. We assessed high‐risk human papillomavirus (HR‐HPV) infection and cervical disease progression among screened WLWH in Zambia.
Methods
Participants underwent visual inspection with acetic acid (VIA), HR‐HPV testing and cervical biopsies at baseline and at follow‐up 30–36 months later. Women with positive VIA results or high‐grade histology were offered treatment. We assessed HR‐HPV and cervical disease prevalence at both timepoints and used multivariable logistic regression to identify factors associated with cervical disease progression and regression.
Results
Among 241 included women, HR‐HPV prevalence declined from 44% (95% confidence interval [CI]: 39%–49%) at baseline to 24% (95% CI: 19%–31%) at follow‐up. High‐grade disease decreased from 25% (95% CI: 20%–31%) to 9% (95% CI: 5%–13%). In analyses adjusted for age, CD4 cell count, HIV RNA viral load, HR‐HPV infection and histological results at baseline, precancer treatment was associated with increased odds of disease regression (adjusted odds ratio [aOR]: 2.74, 95% CI: 1.08–7.06) and reduced odds of progression (aOR: 0.45, 95% CI: 0.11–1.64). One‐third of women with high‐grade disease at follow‐up (7/21) had previously undergone precancer treatment.
Conclusions
Cervical screening and precancer treatment are key to reducing cervical disease progression among WLWH and ultimately achieving cervical cancer elimination, but efforts to improve treatment effectiveness among WLWH must be balanced with the risk of overtreatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.
- Early Detection, Prevention and Infections Branch, International Agency for Research on Cancer, World Health Organization (IARC/WHO), Lyon, France.
- Centre for Infectious Disease Research in Zambia, Lusaka, Zambia.
- Lancet Laboratories, Johannesburg, South Africa.
- Women and Newborn Hospital, University Teaching Hospitals, Lusaka, Zambia.
- University of Alabama at Birmingham, Birmingham, Alabama, USA.
ORCID-Profile: John Andoh, Partha Basu, Eliane Rohner
Förderung
- NIH HHS
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
- World Health Organization
- NIAID NIH HHS
- Swiss Cancer Research Foundation
- National Institutes of Health
Zitieren
APA
Andoh, J., Taghavi, K., Moono, M., Basu, P., Madliwa, T., Mwanahamuntu, M. H., Low, N., Manasyan, A., & Rohner, E. (2025). Cervical intraepithelial neoplasia progression and regression among women living with HIV in Zambia. HIV Medicine. https://doi.org/10.1111/hiv.70134
Vancouver
Andoh J, Taghavi K, Moono M, Basu P, Madliwa T, Mwanahamuntu MH, et al. Cervical intraepithelial neoplasia progression and regression among women living with HIV in Zambia. HIV Medicine. 2025. doi:10.1111/hiv.70134
BibTeX
@article{Andoh2025,
author = {Andoh, John and Taghavi, Katayoun and Moono, Misinzo and Basu, Partha and Madliwa, Thamsanqa and Mwanahamuntu, Mulindi H and Low, Nicola and Manasyan, Albert and Rohner, Eliane},
title = {Cervical intraepithelial neoplasia progression and regression among women living with HIV in Zambia},
journal = {HIV Medicine},
year = {2025},
doi = {10.1111/hiv.70134}
}
EUVIMED